Fibrosis and evidence for epithelial-mesenchymal transition in the kidneys of patients with staghorn calculi

BJU International

Volumn 108, Issue 8, 2011, Pages 1336-1345

  Boonla, Chanchai ^a   Krieglstein, Kerstin ^b   Bovornpadungkitti, Sombat ^c   Strutz, Frank ^d   Spittau, Björn ^b   Predanon, Chagkrapan ^c   Tosukhowong, Piyaratana ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b KHON KAEN HOSPITAL   (Thailand)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

EMT; epithelial mesenchymal transition; inflammation; Kidney stone; renal fibrosis; TGF 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AMMONIUM MAGNESIUM PHOSPHATE; CALCIUM OXALATE; CALCIUM PHOSPHATE; CD68 ANTIGEN; CREATININE; CYTOKERATIN; FIBRONECTIN; TRANSFORMING GROWTH FACTOR BETA1; URIC ACID; VIMENTIN;

ADULT; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDRONEPHROSIS; IMMUNOFLUORESCENCE; IMMUNOPEROXIDASE STAINING; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; MALE; MICROSCOPY; NEPHRITIS; NEPHROLITHIASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYURIA; RISK FACTOR; STAGHORN STONE;

ACTINS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CASE-CONTROL STUDIES; CREATININE; CROSS-SECTIONAL STUDIES; EPITHELIAL-MESENCHYMAL TRANSITION; FIBRONECTINS; FIBROSIS; HUMANS; KERATINS; KIDNEY; KIDNEY TUBULES; MALE; MIDDLE AGED; NEPHROLITHIASIS; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

EID: 79956359072     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10074.x     Document Type: Article

References (48)

1. Tosukhowong P, Boonla C, Ratchanon S, et al,. Crystalline composition and etiologic factors of kidney stone in Thailand: update 2007. Asian Biomed 2007; 1: 87-95
2. Tosukhowong P, Yachantha C, Sasivongsbhakdi T, et al,. Citraturic, alkalinizing and antioxidative effects of limeade-based regimen in nephrolithiasis patients. Urol Res 2008; 36: 149-55
3. Tungsanga K, Sriboonlue P, Futrakul P, Yachantha C, Tosukhowong P,. Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol Res 2005; 33: 65-9 (Pubitemid 40487196)
4. Boonla C, Hunapathed C, Bovornpadungkitti S, et al,. Messenger RNA expression of monocyte chemoattractant protein-1 and interleukin-6 in stone-containing kidneys. BJU Int 2008; 101: 1170-7 (Pubitemid 351502659)
5. Boonla C, Wunsuwan R, Tungsanga K, Tosukhowong P,. Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res 2007; 35: 185-91 (Pubitemid 47312979)
6. Khan SR,. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 2004; 8: 75-88 (Pubitemid 38906629)
7. Worcester EM, Parks JH, Evan AP, Coe FL,. Renal function in patients with nephrolithiasis. J Urol 2006; 176: 600-3 (Pubitemid 43927885)
8. Evan AP, Coe FL, Lingeman JE, et al,. Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 2006; 69: 2227-35 (Pubitemid 43882110)
9. Evan AP, Lingeman JE, Coe FL, et al,. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 2005; 67: 576-91 (Pubitemid 40139849)
10. Zeisberg M, Kalluri R,. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 2004; 82: 175-81 (Pubitemid 38392167)
11. Liu Y,. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-7 (Pubitemid 43323069)
12. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R,. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008; 19: 2282-7
13. Strutz F, Okada H, Lo CW, et al,. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995; 130: 393-405
14. Yang J, Liu Y,. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465-75 (Pubitemid 32947976)
15. Liu Y,. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-22
16. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG,. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341-50 (Pubitemid 34847966)
17. Hertig A, Verine J, Mougenot B, et al,. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 2006; 6: 2937-46
18. Rastaldi MP, Ferrario F, Giardino L, et al,. Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 2002; 62: 137-46 (Pubitemid 34754056)
19. Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF,. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant 2005; 5: 1367-74 (Pubitemid 40839427)
20. Nishitani Y, Iwano M, Yamaguchi Y, et al,. Fibroblast-specific protein 1 is a specific prognostic marker for renal survival in patients with IgAN. Kidney Int 2005; 68: 1078-85 (Pubitemid 43246424)
21. Rossini M, Cheunsuchon B, Donnert E, et al,. Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease. Kidney Int 2005; 68: 2621-8 (Pubitemid 43251008)
22. Evan AP, Coe FL, Lingeman JE, Worcester E,. Insights on the pathology of kidney stone formation. Urol Res 2005; 33: 383-9 (Pubitemid 41752062)
23. Moriyama T, Kawada N, Ando A, et al,. Up-regulation of HSP47 in the mouse kidneys with unilateral ureteral obstruction. Kidney Int 1998; 54: 110-9 (Pubitemid 28288025)
24. Healy KA, Ogan K,. Pathophysiology and management of infectious staghorn calculi. Urol Clin North Am 2007; 34: 363-74 (Pubitemid 47176126)
25. Okun R, Kleeman CR,. Renal disease secondary to metabolic disorders or physiological deficiency states. Calif Med 1967; 107: 8-10
26. Weiner ID, Wingo CS,. Hypokalemia-consequences, causes, and correction. J Am Soc Nephrol 1997; 8: 1179-88 (Pubitemid 27427227)
27. Sriboonlue P, Prasongwattana V, Tungsanga K, et al,. Blood and urinary aggregator and inhibitor composition in controls and renal-stone patients from northeastern Thailand. Nephron 1991; 59: 591-6
28. Tungsanga K, Sriboonlue P, Borwornpadungkitti S, Tosukhowong P, Sitprija V,. Urinary acidification in renal stone patients from northeastern Thailand. J Urol 1992; 147: 325-8
29. Sriboonlue P, Prasongwatana V, Suwantrai S, Bovornpadungkitti S, Tungsanga K, Tosukhowong P,. Nutritional potassium status of healthy adult males residing in the rural northeast Thailand. J Med Assoc Thai 1998; 81: 223-32
30. Yachantha C, Hossain RZ, Yamakawa K, et al,. Effect of potassium depletion on urinary stone risk factors in Wistar rats. Urol Res 2009; 37: 311-6
31. Jungers P, Joly D, Barbey F, Choukroun G, Daudon M,. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 2004; 44: 799-805 (Pubitemid 39445911)
32. Rule AD, Bergstralh EJ, Melton LJ, 3rd, Li X, Weaver AL, Lieske JC,. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 804-11
33. Stankus N, Hammes M, Gillen D, Worcester E,. African American ESRD patients have a high pre-dialysis prevalence of kidney stones compared to NHANES III. Urol Res 2007; 35: 83-7 (Pubitemid 46729146)
34. Vupputuri S, Soucie JM, McClellan W, Sandler DP,. History of kidney stones as a possible risk factor for chronic kidney disease. Ann Epidemiol 2004; 14: 222-8 (Pubitemid 38249337)
35. Saucier NA, Sinha MK, Liang KV, et al,. Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota. Am J Kidney Dis 2010; 55: 61-8
36. Evan AP,. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol 2010; 25: 831-41
37. Evan AP, Lingeman JE, Coe FL, Worcester EM,. Role of interstitial apatite plaque in the pathogenesis of the common calcium oxalate stone. Semin Nephrol 2008; 28: 111-9 (Pubitemid 351400299)
38. Evan A, Lingeman J, Coe FL, Worcester E,. Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int 2006; 69: 1313-8
39. Evan AP, Lingeman JE, Coe FL, et al,. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 2003; 111: 607-16 (Pubitemid 36278579)
40. Evan AP, Lingeman J, Coe F, et al,. Renal histopathology of stone-forming patients with distal renal tubular acidosis. Kidney Int 2007; 71: 795-801 (Pubitemid 46624023)
41. Evan AE, Lingeman JE, Coe FL, et al,. Histopathology and surgical anatomy of patients with primary hyperparathyroidism and calcium phosphate stones. Kidney Int 2008; 74: 223-9 (Pubitemid 351915086)
42. Evan AP, Lingeman JE, Coe FL, et al,. Intra-tubular deposits, urine and stone composition are divergent in patients with ileostomy. Kidney Int 2009; 76: 1081-8
43. Kummeling MT, de Jong BW, Laffeber C, et al,. Tubular and interstitial nephrocalcinosis. J Urol 2007; 178: 1097-103 (Pubitemid 47211053)
44. Strutz F,. How many different roads may a cell walk down in order to become a fibroblast? J Am Soc Nephrol 2008; 19: 2246-8
45. Huang Y, Border WA, Noble NA,. Perspectives on blockade of TGFbeta overexpression. Kidney Int 2006; 69: 1713-4
46. Rashed T, Menon M, Thamilselvan S,. Molecular mechanism of oxalate-induced free radical production and glutathione redox imbalance in renal epithelial cells: effect of antioxidants. Am J Nephrol 2004; 24: 557-68 (Pubitemid 39656672)
47. Yu L, Border WA, Huang Y, Noble NA,. TGF-beta isoforms in renal fibrogenesis. Kidney Int 2003; 64: 844-56
48. Khan SR, Glenton PA, Byer KJ,. Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy- L-proline. Kidney Int 2006; 70: 914-23 (Pubitemid 44285969)